Bispecific T-Cell Engaging Antibodies Against MUC16 Demonstrate Efficacy Against Ovarian Cancer in Monotherapy and in Combination With PD-1 and VEGF Inhibition

Bispecific T-Cell Engaging Antibodies Against MUC16 Demonstrate Efficacy Against Ovarian Cancer in Monotherapy and in Combination With PD-1 and VEGF Inhibition

Immunotherapy for ovarian cancer is an area of intense investigation since the majority of women with relapsed disease develop resistance to conventional cytotoxic therapy. The paucity of safe and validated target antigens has limited the development of clinically relevant antibody-based immunothera...

Full description

Bibliographic Details
Main Authors: Oladapo O. Yeku, Thapi Dharma Rao, Ian Laster, Artem Kononenko, Terence J. Purdon, Pei Wang, Ziyou Cui, Hong Liu, Renier J. Brentjens, David Spriggs
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-04-01
Series:Frontiers in Immunology
Subjects:
ovarian cancer
bispecific antibodies
bispecific engagers
MUC16
MUC16ecto
VEGF
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2021.663379/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2021.663379/full

Similar Items